Aniracetam
Aniracetam is mainly a creativity and verbal-fluency experiment, with historical dosing around 750-1,500 mg/day and human evidence concentrated in older cognitive-disorder literature such as Sourander 1987. The anxiolytic story is interesting but still thin for healthy users.
Aniracetam scored 5.1 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Racetam.
What It Is
Aniracetam scores 5.1/10 because its strongest case is cognition, memory, and anxiety-adjacent mechanisms, with weaker support outside that lane. The best read is practical and narrow: match the intervention to readers evaluating racetam-style cognitive support rather than systemic health claims.
The main evidence anchor is Gouliaev and Senning 1994. Nakamura et al. 2001 adds important context, while Cohen et al. 2021 helps define the safety, sourcing, or regulatory caveat that keeps the score from moving higher.
The key caveat is that human evidence is older and mostly disease-oriented, while current supplement supply quality is uneven. This report treats Aniracetam as a candidate for specific use cases, not a general wellness shortcut.
Terminology
AMPA: A glutamate receptor family involved in fast excitatory signaling. - CYP1A2: A liver enzyme relevant to caffeine and xanthine metabolism. - ER Stress: Endoplasmic-reticulum stress, a cellular protein-folding stress pathway. - MAO-B: Monoamine oxidase B, an enzyme that breaks down dopamine-related monoamines. - NOAEL: No observed adverse effect level in toxicology work.
UDCA: Ursodeoxycholic acid, the unconjugated parent bile acid of TUDCA. - WADA: World Anti-Doping Agency, relevant for athlete prohibited-list risk.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Capsule, powder, tablet, or food form depending on intervention | 750-1,500 mg/day in historical and anecdotal use, often with food because it is fat-soluble | 750-1,500 mg/day in historical and anecdotal use, often with food because it is fat-soluble |
Protocols
Conservative research comparison Mixed
- Dose
- 750-1,500 mg
- Frequency
- As studied or label-directed, with outcome tracking
- Duration
- Single session to 12 weeks depending on endpoint
Research-assistance framing only; avoid unsupervised escalation.
How this score is calculated →
Upside contribution: 0.99
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 1.9 | 0.475 | |
| Breadth of Benefits | 15% | 2.3 | 0.345 | |
| Evidence Quality | 25% | 1.6 | 0.400 | |
| Speed of Onset | 10% | 2.6 | 0.260 | |
| Durability | 10% | 1.8 | 0.180 | |
| Bioindividuality Upside | 15% | 2.2 | 0.330 | |
| Total | 1.990 |
Upside Rationale
Aniracetam scores 5.1/10 because its upside is concentrated in cognition, memory, and anxiety-adjacent mechanisms. The clearest anchor is older dementia and pharmacology literature, with no modern healthy-adult replication base, so the rating rewards the specific use cases while staying conservative about claims beyond them.
Efficacy (3.0/5.0): Aniracetam earns this efficacy score because the best signals map to cognition, memory, and anxiety-adjacent mechanisms. Gouliaev and Senning 1994 is the main anchor, while Nakamura et al. 2001 helps define where the signal remains preliminary.
Breadth of Benefits (2.3/5.0): Aniracetam has limited breadth outside its core lane. The report gives more credit where the evidence matches readers evaluating racetam-style cognitive support rather than systemic health claims, and less where endpoints drift into unrelated systems.
Evidence Quality (2.4/5.0): Aniracetam evidence quality is constrained by sample size, age of the literature, sponsor concentration, or indirect endpoints. Gouliaev and Senning 1994 and Cohen et al. 2021 keep the score useful without overstating certainty.
Speed of Onset (3.4/5.0): Aniracetam can produce faster feedback when the intended effect is acute attention, energy, sleep timing, digestion, or performance. That speed helps users judge fit, but it does not replace longer safety follow-up.
Durability (2.2/5.0): Aniracetam durability is moderate to low when continued dosing, training context, sleep timing, diet, or supply quality drives the result. The score rises only when the benefit can be maintained without chasing dose escalation.
Bioindividuality Upside (2.5/5.0): Aniracetam has meaningful bioindividuality because baseline need, medications, caffeine response, training status, liver or bile context, sleep pressure, and tolerance can change the outcome. Nakamura et al. 2001 is useful for defining that context.
Downside contribution: 0.89 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.8 | 0.540 | |
| Side Effect Profile | 15% | 1.8 | 0.270 | |
| Financial Cost | 5% | 2.4 | 0.120 | |
| Time/Effort Burden | 5% | 1.7 | 0.085 | |
| Opportunity Cost | 5% | 2.2 | 0.110 | |
| Dependency / Withdrawal | 15% | 1.4 | 0.210 | |
| Reversibility | 25% | 1.4 | 0.350 | |
| Total | 1.685 | |||
| Harm subtotal × 1.4 | 1.918 | |||
| Opportunity subtotal × 1.0 | 0.315 | |||
| Combined downside | 2.233 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.893 |
Downside Rationale
Aniracetam downside is driven by human evidence is older and mostly disease-oriented, while current supplement supply quality is uneven. The risk score is highest where user selection, product quality, stimulant load, medical context, or regulation can change the expected result.
Safety (2.4/5.0): Aniracetam safety concerns are manageable for some users and unacceptable for others depending on dose, diagnosis, medication use, and source quality. Nakamura et al. 2001 is the main safety anchor for this dimension.
Side Effects (2.5/5.0): Aniracetam side effects matter because the likely use cases often depend on subjective feel, stimulation, digestion, sleep, or skin response. Gouliaev and Senning 1994 helps frame expected benefits against tolerability.
Interaction Risk (2.0/5.0): Aniracetam interaction risk rises when users combine it with stimulants, sedatives, anticoagulants, liver-active agents, training stress, or disease-specific treatment. The report keeps this dimension separate from general safety.
Supply (3.0/5.0): Aniracetam supply risk reflects labeling accuracy, adulteration, ingredient identity, and whether the market is supplement, prescription, peptide, or gray-market dominated. Cohen et al. 2021 is especially relevant when product trust is part of the risk.
Cost (2.0/5.0): Aniracetam cost risk is not only price per serving. It also includes the cost of chasing weak evidence, lab testing, medical monitoring, or replacing simpler options such as sleep, diet, training, or caffeine management.
Regulatory (2.7/5.0): Aniracetam regulatory risk depends on whether the compound is a normal food, a dietary supplement ingredient, a drug, a sport-restricted substance, or a research peptide. This can be the deciding downside for athletes and cautious users.
Bioindividuality Downside (2.4/5.0): Aniracetam bioindividuality downside is meaningful because personal risk can swing with anxiety, sleep timing, pregnancy, age, liver or kidney status, sport testing, CYP metabolism, and baseline deficiency or excess.
Verdict
Aniracetam is a conditional research candidate rather than a universal recommendation. The score is most favorable when the reader's target matches the highest use-case scores, the product source is credible, and the reader can track a concrete outcome before and after use. The score is least favorable when Aniracetam is used to chase vague optimization, replace higher-certainty basics, or stack with overlapping compounds without a clear reason.
Aniracetam makes the most sense when the reader can define the target outcome in advance, compare Aniracetam with the related reports above, and stop quickly if the result is poor.
❌ Avoid if: Avoid Aniracetam when legal status, athlete testing, medication conflicts, allergy risk, organ disease, pregnancy questions, stimulant sensitivity, or poor sourcing changes the risk picture. Avoid using Aniracetam as a substitute for sleep, nutrition, training, medical care, or well-supported alternatives.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cognition / Focus: 5.0/10
Score: 5.0/10Aniracetam scores 5.0/10 for cognition focus because the human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Isaacson et al. 1991, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Aniracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Memory: 5.0/10
Score: 5.0/10Aniracetam scores 5.0/10 for memory because the most relevant studies involve memory tasks, cognitive impairment, or working-memory endpoints. The strongest support comes from Isaacson et al. 1991, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Aniracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Anxiety: 5.0/10
Score: 5.0/10Aniracetam scores 5.0/10 for anxiety because the most cited anxiolytic case rests on animal and mechanism work rather than human anxiety trials. The strongest support comes from Isaacson et al. 1991, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Aniracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Frequently Asked Questions
What does Aniracetam actually do?
Aniracetam mainly acts through the biology described in this report, and the best concise source is Isaacson et al. 1991. Aniracetam should be read as a research-assistance topic rather than a treatment recommendation. That is why the score separates plausible pathways from proven user value.
How much Aniracetam is typically used?
Aniracetam is usually discussed around 750-1,500 mg/day in historical and anecdotal use, often with food because it is fat-soluble, but dosing depends on context, product quality, and clinician constraints. This report lists research and anecdotal ranges for comparison only. Aniracetam should not be stacked casually with overlapping drugs or stimulants, and higher doses should be treated as a separate risk decision. The safest reading is to compare published ranges with the label and personal tolerance.
What does the human evidence show for Aniracetam?
Aniracetam has an evidence profile led by Isaacson et al. 1991 and the other sources in the evidence table. Aniracetam receives credit when human outcomes exist and loses credit when the work is small, industry-concentrated, disease-specific, or not independently replicated. That is why a popular community use can still receive a modest score when the direct clinical literature is thin.
Is Aniracetam safe long term?
Aniracetam looks safer when dose, source quality, medication conflicts, and stop criteria are handled conservatively. The long-term safety answer is weaker when human follow-up is short, when products are unapproved drugs, or when stimulant effects can affect sleep and cardiovascular comfort. Aniracetam earns a better safety rating only where the evidence base includes ordinary-use tolerability and clear reversibility.
Who should avoid Aniracetam?
Aniracetam should be avoided by readers with relevant medication conflicts, pregnancy questions, severe organ disease, allergy risk, or athlete testing exposure when those concerns apply. Aniracetam also deserves caution when the supply chain is unclear or when the main goal could be met by better-studied options. The report frames these as research guardrails, not individualized medical instructions.
How fast does Aniracetam work?
Aniracetam may feel acute when the mechanism is stimulant-like, but disease or recovery outcomes usually need longer observation. The timeline in this report separates same-day subjective effects from delayed biomarkers and functional changes. Aniracetam should be judged with a preplanned outcome, because vague improvement tracking can make short-lived arousal feel more useful than it is.
How is Aniracetam different from nearby alternatives?
Aniracetam differs from nearby alternatives by mechanism, evidence quality, legality, and product reliability. The related reports linked in the verdict help compare Aniracetam with better-known options before treating the category as interchangeable. A close alternative may have lower subjective novelty but better replication, easier sourcing, or fewer interaction problems, which matters for the final score.
What would make the Aniracetam score change?
Aniracetam would score higher with larger independent trials, longer safety follow-up, clearer dosing, and direct evidence for the main use cases. Aniracetam would score lower if safety signals strengthen, product quality worsens, or better alternatives cover the same goal with less uncertainty. The score is therefore a snapshot of current evidence, not a permanent verdict.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
Aniracetam could move meaningfully if the evidence base changes because several current uncertainties are fixable. Independent trials could raise confidence, longer follow-up could clarify safety, and better product testing could reduce sourcing concern. Aniracetam could also fall if larger studies fail to replicate the small positive findings, if regulatory scrutiny increases, or if real-world users report a pattern of sleep, mood, digestive, or cardiovascular problems. The scenarios below show how the same intervention can move across tiers without changing the scoring method, simply by improving or weakening the underlying facts.
| Scenario | Likely score |
|---|---|
| Larger independent human trials replicate the best outcome and safety stays clean. | 6.3 / 10 👍 Worth trying |
| Evidence stays mostly small, sponsor-linked, or disease-specific. | 5.1 / 10 ⚖️ Neutral |
| New safety, sourcing, regulatory, or replication concerns appear. | 3.9 / 10 ⚠️ Caution |
BioHarmony Engine v1.0
Key Evidence Sources
- Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- Pharmacokinetics of aniracetam and its metabolites in rats. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
- Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders. Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive
- Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent. Reviewed in 2026 for citation integrity; useful for mechanism or outcome context but not treated as universal proof.
- Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
- Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Reviewed in 2026 as clinical or mechanistic background; sample, year, and endpoint directness shape the confidence rating.
- Kratom-Related Deaths. Reviewed in 2026 for citation integrity; useful for mechanism or outcome context but not treated as universal proof.
- Five Unapproved Drugs Found in Cognitive Enhancement Supplements. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Nakamura 2002: Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries.
Pre-RCT-Era Pharmacology and Use
Citations: Aniracetam. An overview of its pharmacodynamic and pharmacokinetic ..., Anxiolytic effects of aniracetam in three different mouse models of..., Five Unapproved Drugs Found in Cognitive Enhancement Supplements
Traditional Medicine Systems
Citations: Aniracetam. An overview of its pharmacodynamic and pharmacokinetic ..., Anxiolytic effects of aniracetam in three different mouse models of..., Five Unapproved Drugs Found in Cognitive Enhancement Supplements
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Sleep Duration During | Expected Watch
- Mood Score During | Expected Watch
Pulse Dimensions to Watch
- Calm During | Expected Up | Primary
- Drive During | Expected Up | Secondary
- Sleep During | Expected Watch | Secondary
Subjective Signals (Daily Voice Card)
- Social Ease Scale 1-5 | During | Expected Up
- Headache Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Worsening anxiety, agitation, or insomnia
- Unknown-source product or mislabeled capsules
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 0.990 − 0.893 = 0.097
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.097 / 5) × 5 = 5.1 / 10
Further learning
65+ Nootropic Ingredients I’ve Supplemented (Rated & Reviewed)
I've tested all kinds of nootropic ingredients & brain-boosting supplements. Here's a simple rundown, my personal ratings and mini review, and practical uses of…
Unconventional Ways to Power Up Your Brain & Perform Like an Elite Athlete
Did you know you could optimize your brain & body performance using nootropics safely & effectively? We discuss using substances like caffeine, dynamine &…
